



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ariel Fletcher

Ariel Fletcher

11/27/2002

Date of Deposit

Applicant:	Brooks, et al.)	
)	
Serial No.:	09/081,522)	Group Art Unit: 1644
)	
Filed:	May 19, 1998)	Examiner: P. Gambel
)	
Title:	INHIBITION OF ANGIOGENESIS)	
	IN DISEASE STATES WITH AN)	
	ANTI- $\alpha_v\beta_3$ MONOCLONAL)	Our Ref.: TSRI 419.0 Con 1
	ANTIBODY (AS AMENDED))	

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR §1.56, Applicants hereby submit the present Supplemental Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Supplemental

Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(c). The statement is accompanied by a check in the amount of \$180.00 as payment of the fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c)(2).


Also, in accordance with 37 CFR §1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

11/27/02
Date

Emily Holmes
Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

FORM TOL 449 P U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 	ATTY DOCKET NO. TSRI 419.0 C1	SERIAL NO. 09/081,522
INFORMATION DISCLOSURE STATEMENT OF THE APPLICANT	APPLICANT Brooks, et al.	
	FILING DATE 05/19/98	GROUP 1644

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

[illegible]

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

By Hand Delivery

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Brooks, et al.)	
)	
Serial No.:	09/081,522)	Group Art Unit: 1644
)	
Filed:	May 19, 1998)	Examiner: P. Gambel
)	
Title:	INHIBITION OF ANGIOGENESIS)	
	IN DISEASE STATES WITH AN)	Confirmation No. 1607
	ANTI- α v β 3 MONOCLONAL)	
	ANTIBODY (AS AMENDED))	Our Ref.: TSRI 419.0 Con 1
)	

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 and § 1.97

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicant hereby directs the Examiner's attention to the references listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant." A legible copy of the two attached references are being submitted herewith.

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.


Since this Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action after the filing of a Request for Continued Examination under §1.114, the fee required to be filed with the accompanying Supplemental Information Disclosure Statement has been estimated to be \$0.00. However, should the Patent Office determine otherwise, please charge the required fee to Deposit Account No. 19-0962. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

September 16, 2003

Date

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, California 92037
(858) 784-2937
Enclosure


Emily Holmes, Reg. No. 40,652

ATTY DOCKET NO.

TSRI 419.0 C1

APPLICATION NO

09/081,522

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Brooks et al.

FILING DATE

05/19/98

GROUP

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,766,591	6/16/98	Brooks et al.			
	A02						
	A03						
	A04						
	A05						
	A06						
	A07						
	A08						
	A09						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01							
	B02							
	B03							
	B04							
	B05							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Gutheil, et al., "Targeted Antiangiogenic Therapy for Cancer Using vitaxin: A Humanized Monoclonal Antibody to the Integrin $\alpha_v\beta_3$ ", Clin.Cancer Research 6: 3056-3061 (2000).
	C02	
	C03	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this REQUEST and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450; Alexandria, VA 22313-1450.

Ariel Fletcher

Ariel Fletcher

12/29/2003

Date of Deposit

Applicant:	Brooks, et al.)	
)	
Serial No.:	09/081,522)	Group Art Unit: 1644
)	
Filed:	May 19, 1998)	Examiner: P. Gambel
)	
Title:	INHIBITION OF ANGIOGENESIS)	
	IN DISEASE STATES WITH AN)	Confirmation No. 1607
	ANTI- α v β 3 MONOCLONAL)	
	ANTIBODY (AS AMENDED))	Our Ref.: TSRI 419.0 Con 1

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 and §1.97

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to the references listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant." A legible copy of the fifteen attached references are being submitted herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Since this Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action after the filing of a Request for Continued

December 29, 2003


Thomas Fitting, Reg. No. 34,163

Date _____

- 2 -

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. TSRI 419.0 C1	APPLICATION NO 09/081,522
	APPLICANT Brooks et al.	
	FILING DATE 05/19/98	GROUP 1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,578,704	11/26/96	Kim			
	A02	5,652,109	7/29/97	Kim			
	A03	5,652,110	7/29/97	Kim			
	A04	5,677,181	10/14/97	Parish			
	A05	5,874,081	02/23/99	Parish			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 94/10331	5/11/94					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," <u>Cancer Research</u> 58: 485-490 (1998).
	C02	Carmeliet, "Integrin indecision," <u>Nature Medicine</u> 8: 14-16 (2002).
	C03	Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," <u>Proc. Natl. Acad. Sci USA</u> 84: 6471-6475 (1987).
	C04	Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" <u>Nature Medicine</u> 8:193-194 (2002).
	C05	Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti $\alpha_v\beta_3$) Antibody in Patients with Metastatic Cancer," <u>Cancer Biotherapy & Radiopharmaceuticals</u> 16: 125-132 (2001).
	C06	Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," <u>Proc. Natl. Acad. Sci. USA</u> 95: 8910-8915 (1998).
	C07	Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β_1 integrin or β_1 and β_3 integrins," <u>Nature Medicine</u> 8: 27-34 (2002).
	C08	Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," <u>J. Mol. Biol.</u> 255: 28-43 (1996).
	C09	Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," <u>J. Mol. Biol.</u> 263: 551-567 (1996).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.


Thomas Fitting, Reg. No. 34,163

Nov 12, 1999
Date

Applicant	:	Brooks, et al.)
) Group Art Unit: 1648
Serial No.	:	09/081,522)
)
Filed	:	May 19, 1998) Examiner: Unknown
)
For	:	METHODS AND COMPOSITIONS)
		USEFUL FOR INHIBITION OF)
		ANGIOGENESIS) Our Ref. TSRI 419.0C1
)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information

Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application/before the mailing date of a first Office Action.

Also, in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

Dated: 3/12/99

By Thomas Fitting
Thomas Fitting, Reg. No. 34,163

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(619) 784-2937

LL\C:\WP\IDS\MER0046P.IDS

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.
TSRI 419.0 Con 1

SERIAL NO.
09/081,522

APPLICANT
Brooks, et al

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

FILING DATE
5/19/98

GROUP
1648

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	5,092,885	3/3/92	U.S. Patent			
	5,112,946	5/12/92	U.S. Patent			
	5,192,744	3/9/93	U.S. Patent			
	5,202,352	4/13/93	U.S. Patent			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	8905155	6/15/89	PCT			
	0 576 898 A2	6/15/93	European Patent			
	0 578 083 A2	6/26/93	European Patent			
	8906356	7/27/89	PCT			
	9320229	10/14/93	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

1	Davis, et al., "Identification of a Role of the Vitronectin Receptor and Protein Kinase C in the Induction of Endothelial Cell Vascular Formation", <u>J. of Cell. Biochem.</u> 51: 206-218 (1993)
2	Folkman, et al., "Angiogenic Factors", <u>Science</u> 235: 442-447 (1987)
3	Moses, et al., "Identification of an Inhibitor of Neovascularization from Cartilage", <u>Science</u> 248: 1408-1410 (1990)
4	Folkman, et al., "Inhibition of Angiogenesis", <u>Cancer Bio.</u> 3: 89-96 (1992)
5	Blood, et al., "Tumor Interactions with the Vasculature: Angiogenesis and Tumor Metastasis", <u>Biochim. et Biophys. Acta</u> 1032: 89-118 (1990)
6	Ingber, et al., "Inhibition of Angiogenesis through Modulation of Collagen Metabolism", <u>Lab. Invest.</u> 59 (1): 44-51 (1988)
7	Aumailley, et al., "Arg-Gly-Asp Constrained within Cyclic Pentapeptides: Strong and Selective Inhibitors of Cell Adhesion to Vitronectin and Laminin - Fragment P1", <u>Fed. of Euro. Biochem. Soc.</u> 291 (1): 50-54 (1991)
8	Choi, et al., "Inhibition of Neointimal Hyperplasia by Blocking $\alpha_v\beta_3$ Integrin with a Small Peptide Antagonist GpenGRGDSPCA", <u>J. of Vasc. Surg.</u> 19: 125-134 (1994)
9	Nicosia, et al., "Inhibition of Angiogenesis in vitro by Arg-Gly-Asp-Containing Synthetic Peptide", <u>Amer. Jour. of Patho.</u> 138 (4): 829-833 (1991)
10	Cheresh, et al., "Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor", <u>J. of Bio. Chem.</u> 262 (36): 17703-17711 (1987)
11	Leavesley, et al., "Integrin β_1 - and β_3 -mediated Endothelial Cell Migration is Triggered through Distinct Signaling Mechanisms", <u>J. of Cell Biol.</u> 121: 163-170 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.
TSRI 419.0 Con 1

SERIAL NO.
09/081,522

APPLICANT
Brooks, et al.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

FILING DATE
5/19/98

GROUP
1648

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	12	Swerlick, et al., "Expression and Modulation of the Vitronectin Receptor on Human Dermal Microvascular Endothelial Cells", <u>J. of Inves. Derm.</u> 99 (6): 715-722 (1992)
	13	Brooks, et al., "Subtractive Immunization Yields Monoclonal Antibodies that Specifically Inhibit Metastasis", <u>J. of Cell Biol.</u> 122 (6): 1351-1359 (1993)
	14	Nip, et al., "Human Melanoma Cells Derived from Lymphatic Metastases Use Integrin $\alpha_5\beta_1$ to Adhere to Lymph Node Vitronectin", <u>J. Clin. Invest.</u> 90: 1406-1413 (1992)
	15	Jackson, et al., "Isolation and Propagation of Endothelial Cells Derived from Rheumatoid Synovial Microvasculature", <u>Ann. of the Rheu. Dis.</u> 48: 733-736 (1989)
	16	Waldman, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy", <u>Science</u> 252: 1657-1662 (1991)
	17	Brooks, et al., "Requirement of Vascular Integrin $\alpha_5\beta_1$ for Angiogenesis", <u>Science</u> 264: 569-570 (1994)
	18	Chuntharapai, et al., "Blocking Monoclonal Antibodies to $\alpha V\beta 3$ Integrin: A Unique Epitope of $\alpha V\beta 3$ Integrin is Present on Human Osteoclasts", <u>Exper. Cell Res.</u> 205: 345-352 (1993)
	19	Osband, et al., "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy", <u>Imm. Today</u> 11 (6): 193-195 (1990)
	20	Ausprunk, et al., "Vascularization of Normal and Neoplastic Tissues Grafted to the Chick Chorioallantois", <u>Amer. J. of Path.</u> 79 (3): 597-610 (1975)
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.
TSRI 419.0 Con 1

SERIAL NO.
09/081,522

APPLICANT
Brooks, et al.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

FILING DATE
5/19/98

GROUP
1648

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	21	Cheresh, et al., "Recognition of Distinct Adhesive Sites on Fibrinogen by Related Integrins on Platelets and Endothelial Cells", <u>Cell</u> 58: 945-953 (1989)
	22	D'Amato, et al., "Thalidomide is an Inhibitor of Angiogenesis", <u>Proc. Natl. Acad. Sci. USA</u> 91: 4082-4085 (1994)
	23	Leibovich, et al., "Macrophage-induced Angiogenesis is Mediated by Tumour Necrosis Factor- α ", <u>Nature</u> 329: 630-632 (1987)
	24	Pfaff, et al., "Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by α lib β 3, and α 5 β 1 Integrins", <u>J. of Biol. Chem.</u> 269 (32): 20233-20238 (1994)
	25	Yan, et al., "Human/Severe Combined Immunodeficient Mouse Chimeras: An Experimental in Vivo Model System to Study the Regulation of Human Endothelial Cell-Leukocyte Adhesion Molecules", <u>J. Clin. Invest.</u> 91: 986-996 (1993)
	26	Gurath, et al., "Conformation/Activity Studies of Rationally Designed Potent Anti-Adhesive RGD Peptides", <u>Eur. J. Biochem</u> 210: 911-921 (1992)
	27	Leven, et al., "Extracellular Matrix Stimulation of Guinea Pig Megakaryocyte Proplatelet Formation in vitro Is Mediated Through the Vitronectin Receptor", <u>Exp. Hematol.</u> 20: 1316-1322 (1992)
	28	Lafrenie, et al., "Up-regulated Biosynthesis and Expression of Endothelial Cell Vitronectin Receptor Enhances Cancer Cell Adhesion", <u>Canc. Res.</u> 52: 2202-2208 (1992)
	29	Klein, et al., "Basic Fibroblast Growth Factor Modulates Integrin Expression in Microvascular Endothelial Cells", <u>Mol. Bio. of the Cell</u> 4: 973-982 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

MC/C:\WP\DIS\MER0046P.449

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ariel Fletcher

Ariel Fletcher

10/10/2001

Date of Deposit

Applicant:	Brooks, et al.)	
Serial No.:	09/081,522)	Group Art Unit: 1644
Filed:	May 19, 1998)	Examiner: P. Gambel
Title:	INHIBITION OF ANGIOGENESIS IN DISEASE STATES WITH AN ANTI- $\alpha_v\beta_3$ MONOCLONAL ANTIBODY (AS AMENDED))	Our Ref.: TSRI 419.0 Con 1

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR §1.56, Applicants hereby submit the present Supplemental Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.


Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Supplemental Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(c). The statement is accompanied by a check in the amount of \$180.00 as payment of the fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c)(2).

Also, in accordance with 37 CFR §1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

October 10, 2001
Date


Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TSRI 419.0 Con 1	SERIAL NO. 09/081,522
	APPLICANT Brooks, et al.	
	FILING DATE May 19, 1998	GROUP 1644

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	5,575,815	11/19/96	Slepian, et al.			
	5,849,692	12/15/98	Jonczyk, et al.			
	5,968,902	10/19/99	Scarborough, et al.			
	5,981,478	11/9/99	Ruoslahti, et al.			
	5,866,540	2/2/99	Jonczyk, et al.			
	5,135,919	8/4/92	Folkman, et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	95/28426	10/26/95	PCT			
	97/14716	4/24/97	PCT			
	0 770 622 A	5/2/97	EPO			
	89/06536	7/27/89	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

1	Matsuno, et al., Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation, 1994, <i>Circulation</i> , 90(5):2203-2205.
2	Timar, et al., The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells, 1996, <i>Eur. J. Cancer</i> , 32A(1):152-159.
3	Aimes, et al., Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation, 1994, <i>Biochem J.</i> , 300:729-736.
4	Friedlander, et al., Definition of two angiogenic pathways by distinct α v integrins, 1995, <i>Science</i> , 270:1500-1502.
5	Pfaff, et al., Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins α Ib β 3, α v β 3 and α 5 β 1 and in cell adhesion inhibition, 1994, <i>Cell Adhes. Commun.</i> , 2(6):491-501.
6	Smith, et al., Interaction of integrins α v β 3 and glycoprotein IIb-IIIa with fibrinogen, 1990, <i>J. Biol. Chem.</i> , 265:12267-12271.
7	Mueller, et al., Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells, <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 1991, 4(2):99-106.
8	Ossowski, et al., Experimental model for quantitative study of metastasis, 1980, <i>Cancer Res.</i> , 40:2300-2309.
9	Drake, et al., A antagonist of integrin α v β 3 prevent maturation of blood vessels during embryonic neovascularization, 1995, <i>J. Cell Sci.</i> , 108:2655-2661.

EXAMINER	DATE CONSIDERED
----------	-----------------

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TSRI 419.0 Con 1	SERIAL NO. 09/081,522
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Brooks, et al.	
	FILING DATE May 19, 1998	GROUP 1644

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	95/14714	6/1/95	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

10	Hammes, et al., Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, 1996, <i>Nature Med.</i> , 2(5):529-533.
11	Brooks, et al., Integrin $\alpha v \beta 3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, 1994, <i>Cell</i> , 79:1157-1164.
12	Clark, et al, Transient functional expression of $\alpha v \beta 3$ on vascular cells during wound repair, 1996, <i>Am. J Pathol.</i> , 148:1407-1421.
13	Bauer, et al., In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins and integrins, 1992, <i>J. Cell. Physiol.</i> , 153:437-449.
14	Ingber, Extracellular matrix as a solid state regulator of angiogenesis: identification of new targets for anti-cancer therapy, 1992, <i>Seminars in Cancer Biology</i> , 3:57-63.
15	Hardan, et al., Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptidic Arg-Gly-Asp mimetics, 1993, <i>Intl. J. Cancer</i> , 55:1023-1028.
16	Hynes, Integrins: versatility, modulation, and signaling in cell adhesion, 1992, <i>Cell</i> , 69:11-25.
17	Lehmann, et al., A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins $\alpha v \beta 3$, $\alpha v \beta 5$ and $\alpha v \beta 6$, 1994, <i>Cancer Res.</i> , 54:2102-2107.
EXAMINER	
DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TSRJ 419.0 Con 1	SERIAL NO. 09/081,522
	APPLICANT Brooks, et al.	
	FILING DATE May 19, 1998	GROUP 1644

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

18	Pierschbacher, et al., Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion, 1987, <i>J. Biol. Chem.</i> , 262:17294-17296.
19	Folkman, et al., Angiogenesis, 1992, <i>J. Biol. Chem.</i> , 267:10931-10934.
20	Teicher, et al., Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, 1994, <i>Intl. J. Cancer</i> , 57:920-925.
21	Saiki, et al., Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly (RGD), 1990, <i>Jpn. J. Cancer Res.</i> , 81:668-675.
22	
23	
24	
25	
26	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.